PUBLISHER: BIS Research | PRODUCT CODE: 1650833
PUBLISHER: BIS Research | PRODUCT CODE: 1650833
Europe Hematologic Malignancies Testing Market: Focus on Product, Platform, Disease, End User, and Country - Analysis and Forecast, 2024-2033
Introduction to Europe Hematologic Malignancies Testing Market
The Europe hematologic malignancies testing market was valued at $921.3 million in 2024 and is expected to reach $2,620.8 million by 2033, growing at a CAGR of 12.32% during the forecast period 2024-2033. Detecting and tracking blood cancers like leukemia, lymphoma, and myeloma is the primary focus of the Europe Hematologic Malignancies Testing Market. The market is expanding significantly due to the increasing incidence of these malignancies and ongoing technological advancements. Key diagnostic technologies are essential for accurate diagnosis, prognosis, and personalized treatment planning. These technologies include next-generation sequencing (NGS), polymerase chain reaction (PCR), flow cytometry, and immunohistochemistry.
A rise in clinical research and trials, the growing burden of hematologic cancers, and the growing demand for precise diagnostic solutions are the main factors propelling the market's growth. The demand for hematologic malignancy testing kits and services is also being driven by increased government funding and healthcare initiatives that support early detection and treatment. Continuous developments in molecular diagnostics have produced more innovative and effective testing solutions.
| KEY MARKET STATISTICS | |
|---|---|
| Forecast Period | 2024 - 2033 |
| 2024 Evaluation | $921.3 Million |
| 2033 Forecast | $2,620.8 Million |
| CAGR | 12.32% |
Additionally, the expansion of testing accessibility through hospitals, specialized diagnostic centers, and online healthcare platforms is improving patient access across Europe. As precision medicine and targeted therapies gain traction, the demand for hematologic malignancy testing is expected to rise, fostering market growth across the region.
Market Introduction
The Europe Hematologic Malignancies Testing Market is expanding rapidly due to the increasing prevalence of blood cancers such as leukemia, lymphoma, and multiple myeloma. Developments in diagnostic technologies, including flow cytometry, polymerase chain reaction (PCR), next-generation sequencing (NGS), and immunohistochemistry, are improving prognosis, treatment planning, and early detection.
Growing demand for personalized medicine, expanding clinical trials, and increased research activities are important market drivers. Further propelling market expansion are government programs and healthcare investments targeted at early cancer detection. Market expansion is also being influenced by the use of liquid biopsy for minimal residual disease (MRD) monitoring and the incorporation of artificial intelligence (AI) in genomic testing.
The Europe Hematologic Malignancies Testing Market is expected to grow steadily due to the growing use of precision medicine and the expanded accessibility of testing options via online and hospital platforms, which will enhance patient outcomes and treatment approaches throughout the region.
Market Segmentation:
Segmentation 1: by Product
- Kits
- Services
Segmentation 2: by Platform
- Polymerase Chain Reaction (PCR)
- Next-Generation Sequencing (NGS)
- Fluorescence In-Situ Hybridization (FISH)
- Immunohistochemistry (IHC)
- Flow Cytometry
- Other Platforms
Segmentation 3: by Disease
- Leukemia
- Lymphoma
- Multiple Myeloma
- Myeloproliferative Neoplasms
- Myelodysplastic Syndrome
Segmentation 4: by End User
- Specialty Clinics and Hospitals
- Diagnostic Laboratories
- Reference Laboratories
Segmentation 5: by Region
- Germany
- U.K.
- France
- Italy
- Spain
- Denmark
- Rest-of-Europe
How can this report add value to an organization?
Product/Innovation Strategy: The Europe hematologic malignancies testing market has been segmented based on various categories, such as products, platforms, diseases, and end users. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.
Competitive Strategy: The Europe hematologic malignancies testing market is a highly fragmented market, with many smaller and private companies constantly entering the market. Key players in the Europe hematologic malignancies testing market analyzed and profiled in the study involve established players that offer various kinds of products and services.
Key Market Players and Competition Synopsis
The companies profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.
Some prominent names established in this market are:
- F. Hoffmann-La Roche Ltd.
- ICON plc
- QIAGEN N.V.
- DiaSorin S.p.A
- ELITech Group
Table of Contents
Executive Summary
Scope and Definition
1 Europe Hematologic Malignancies Testing Market: Market Overview
- 1.1 Introduction
- 1.2 Types of Hematologic Malignancies Diagnostic Tests
- 1.3 Market Footprint and Growth Potential
2 Hematologic Malignancies Testing Market: Industry Analysis
- 2.1 Key Trends: Current and Future Impact Assessment
- 2.1.1 Growing Utilization of Next-Generation Sequencing and Artificial Intelligence in Hematologic Malignancies Testing
- 2.1.2 Increasing Partnerships, Alliances, and Business Expansions among Key Players
- 2.2 Regulatory Framework
- 2.2.1 Regulatory Framework in Europe
- 2.3 COVID-19's Impact on Cancer Diagnostic Market
- 2.4 Supply Chain Analysis
- 2.4.1 Key Entities in Supply Chain
- 2.5 Pricing Analysis
- 2.6 Comparative Analysis of Hematologic Malignancies Test by Different Parameters
3 Region
- 3.1 Regional Summary
- 3.2 Drivers and Restraints
- 3.3 Europe
- 3.3.1 Regional Overview
- 3.3.2 Driving Factors for Market Growth
- 3.3.3 Factors Challenging the Market
- 3.3.4 Germany
- 3.3.5 U.K.
- 3.3.6 Spain
- 3.3.7 Italy
- 3.3.8 France
- 3.3.9 Denmark
- 3.3.10 Rest-of-Europe
4 Europe Hematologic Malignancies Testing Market - Competitive Benchmarking and Company Profiles
- 4.1 Key Strategies and Development
- 4.1.1 Partnerships, Alliances, and Business Expansions
- 4.1.2 Regulatory and Legal Activities
- 4.1.3 New Offerings
- 4.1.4 Mergers and Acquisitions
- 4.2 Market Share
- 4.3 Company Profiles
- 4.3.1 F. Hoffmann-La Roche Ltd.
- 4.3.1.1 Overview
- 4.3.1.2 Top Products
- 4.3.1.3 Top Competitors
- 4.3.1.4 Key Customers
- 4.3.1.5 Key Personnel
- 4.3.1.6 Corporate Strategies
- 4.3.1.7 Analyst View
- 4.3.2 ICON plc
- 4.3.2.1 Overview
- 4.3.2.2 Top Products
- 4.3.2.3 Top Competitors
- 4.3.2.4 Top Customers
- 4.3.2.5 Key Personnel
- 4.3.2.6 Analyst View
- 4.3.3 QIAGEN N.V.
- 4.3.3.1 Overview
- 4.3.3.2 Top Products
- 4.3.3.3 Top Competitors
- 4.3.3.4 Top Customers
- 4.3.3.5 Key Personnel
- 4.3.3.6 Corporate Strategies
- 4.3.3.7 Analyst View
- 4.3.4 DiaSorin S.p.A
- 4.3.4.1 Overview
- 4.3.4.2 Top Products
- 4.3.4.3 Top Competitors
- 4.3.4.4 Top Customers
- 4.3.4.5 Key Personnel
- 4.3.4.6 Corporate Strategies
- 4.3.4.7 Analyst View
- 4.3.5 ELITech Group
- 4.3.5.1 Overview
- 4.3.5.2 Top Products
- 4.3.5.3 Top Competitors
- 4.3.5.4 Top Customers
- 4.3.5.5 Analyst View
- 4.3.1 F. Hoffmann-La Roche Ltd.
5 Research Methodology
- 5.1 Data Sources
- 5.1.1 Primary Data Sources
- 5.1.2 Secondary Data Sources
- 5.1.3 Data Triangulation
List of Figures
- Figure 1: Europe Hematologic Malignancies Testing Market, $Million, 2024, 2028 and 2033
- Figure 2: Hematologic Malignancies Testing Market (by Region), $Million, 2023, 2027, and 2033
- Figure 3: Europe Hematologic Malignancies Testing Market (by Product), $Million, 2023, 2027, and 2033
- Figure 4: Europe Hematologic Malignancies Testing Market (by Platform), $Million, 2023, 2027, and 2033
- Figure 5: Europe Hematologic Malignancies Testing Market (by Disease), $Million, 2023, 2027, and 2033
- Figure 6: Europe Hematologic Malignancies Testing Market (by End User), $Million, 2023, 2027, and 2033
- Figure 7: Europe Hematologic Malignancies Testing Market, Recent Developments
- Figure 8: Classification of Hematologic Malignancies
- Figure 9: Europe Hematologic Malignancies Testing Market, $Million, 2022-2033
- Figure 10: Hematologic Malignancies Testing Market Vs TAM, 2022-2033
- Figure 11: Share of Partnerships, Alliances, and Business Expansions vs. Other Strategies
- Figure 12: Some of the Key Partnerships, Alliances, and Business Expansions and their Impact on the Global Sequencing Market
- Figure 13: Workflow for the IVD Product Approval
- Figure 14: Medical Research Cycle Interruption during the COVID-19 Pandemic
- Figure 15: Hematologic Malignancies Testing Supply Chain Analysis
- Figure 16: Germany Hematologic Malignancies Testing Market, $Million, 2022-2033
- Figure 17: Germany Hematologic Malignancies Testing Market, Test Volume, Thousands, 2022-2033
- Figure 18: U.K. Hematologic Malignancies Testing Market, $Million, 2022-2033
- Figure 19: U.K. Hematologic Malignancies Testing Market, Test Volume, Thousands, 2022-2033
- Figure 20: Spain Hematologic Malignancies Testing Market, $Million, 2022-2033
- Figure 21: Spain Hematologic Malignancies Testing Market, Test Volume, Thousands, 2022-2033
- Figure 22: Italy Hematologic Malignancies Testing Market, $Million, 2022-2033
- Figure 23: Italy Hematologic Malignancies Testing Market, Test Volume, Thousands, 2022-2033
- Figure 24: France Hematologic Malignancies Testing Market, $Million, 2022-2033
- Figure 25: France Hematologic Malignancies Testing Market, Test Volume, Thousands, 2022-2033
- Figure 26: Denmark Hematologic Malignancies Testing Market, $Million, 2022-2033
- Figure 27: Denmark. Hematologic Malignancies Testing Market, Test Volume, Thousands, 2022-2033
- Figure 28: Rest-of-Europe Hematologic Malignancies Testing Market, Test Volume, Thousands, 2022-2033
- Figure 29: Partnerships, Alliances, and Business Expansions Activities, January 2020-May 2024
- Figure 30: Regulatory and Legal Activities, January 2020-May 2024
- Figure 31: New Offerings, January 2020-May 2024
- Figure 32: Mergers and Acquisitions, January 2020-May 2024
- Figure 33: Europe Hematologic Malignancies Testing Market, Market Share (by Company)
- Figure 34: Data Triangulation
- Figure 35: Assumptions and Limitations
List of Tables
- Table 1: Market Snapshot
- Table 2: Hematologic Malignancies Testing Market, Market Opportunities
- Table 3: Diagnostic Tests for Hematologic Malignancies
- Table 4: Current and Future Impact of Trends
- Table 5: Effect of COVID-19 on Cancer Care throughout the World
- Table 6: Pricing Analysis (by Platform Testing)
- Table 7: Comparative Analysis of Hematologic Malignancies Test
- Table 8: Hematologic Malignancies Testing Market (by Region), $Million, 2022-2033
- Table 9: Hematologic Malignancies Testing Market (by Country), $Million, 2022-2033
- Table 10: Europe Hematologic Malignancies Testing Market (by Product), $Million, 2022-2033
- Table 11: Europe Hematologic Malignancies Testing Market (by Platform), $Million, 2022-2033
- Table 12: Europe Hematologic Malignancies Testing Market (by Diseases), $Million, 2022-2033
- Table 13: Europe Hematologic Malignancies Testing Market (by End User), $Million, 2022-2033
- Table 14: Germany Hematologic Malignancies Testing Market, Test Volume (by Platform), Thousands, 2022-2033
- Table 15: Germany Hematologic Malignancies Testing Market, Test Volume (by Diseases), Thousands, 2022-2033
- Table 16: Germany Hematologic Malignancies Testing Market, Test Volume (by End User), Thousands, 2022-2033
- Table 17: Germany Hematologic Malignancies Testing Market (by Product), $Million, 2022-2033
- Table 18: Germany Hematologic Malignancies Testing Market (by Platform), $Million, 2022-2033
- Table 19: Germany Hematologic Malignancies Testing Market (by Diseases), $Million, 2022-2033
- Table 20: Germany Hematologic Malignancies Testing Market (by End User), $Million, 2022-2033
- Table 21: U.K. Hematologic Malignancies Testing Market, Test Volume (by Platform), Thousands, 2022-2033
- Table 22: U.K. Hematologic Malignancies Testing Market, Test Volume (by Diseases), Thousands, 2022-2033
- Table 23: U.K. Hematologic Malignancies Testing Market, Test Volume (by End User), Thousands, 2022-2033
- Table 24: U.K. Hematologic Malignancies Testing Market (by Product), $Million, 2022-2033
- Table 25: U.K. Hematologic Malignancies Testing Market (by Platform), $Million, 2022-2033
- Table 26: U.K. Hematologic Malignancies Testing Market (by Diseases), $Million, 2022-2033
- Table 27: U.K. Hematologic Malignancies Testing Market (by End User), $Million, 2022-2033
- Table 28: Spain Hematologic Malignancies Testing Market, Test Volume (by Platform), Thousands, 2022-2033
- Table 29: Spain Hematologic Malignancies Testing Market, Test Volume (by Diseases), Thousands, 2022-2033
- Table 30: Spain Hematologic Malignancies Testing Market, Test Volume (by End User), Thousands, 2022-2033
- Table 31: Spain Hematologic Malignancies Testing Market (by Product), $Million, 2022-2033
- Table 32: Spain Hematologic Malignancies Testing Market (by Platform), $Million, 2022-2033
- Table 33: Spain Hematologic Malignancies Testing Market (by Diseases), $Million, 2022-2033
- Table 34: Spain Hematologic Malignancies Testing Market (by End User), $Million, 2022-2033
- Table 35: Italy Hematologic Malignancies Testing Market, Test Volume (by Platform), Thousands, 2022-2033
- Table 36: Italy Hematologic Malignancies Testing Market, Test Volume (by Diseases), Thousands, 2022-2033
- Table 37: Italy Hematologic Malignancies Testing Market, Test Volume (by End User), Thousands, 2022-2033
- Table 38: Italy Hematologic Malignancies Testing Market (by Product), $Million, 2022-2033
- Table 39: Italy Hematologic Malignancies Testing Market (by Platform), $Million, 2022-2033
- Table 40: Italy Hematologic Malignancies Testing Market (by Diseases), $Million, 2022-2033
- Table 41: Italy Hematologic Malignancies Testing Market (by End User), $Million, 2022-2033
- Table 42: France Hematologic Malignancies Testing Market, Test Volume (by Platform), Thousands, 2022-2033
- Table 43: France Hematologic Malignancies Testing Market, Test Volume (by Diseases), Thousands, 2022-2033
- Table 44: France Hematologic Malignancies Testing Market, Test Volume (by End User), Thousands, 2022-2033
- Table 45: France Hematologic Malignancies Testing Market (by Product), $Million, 2022-2033
- Table 46: France Hematologic Malignancies Testing Market (by Platform), $Million, 2022-2033
- Table 47: France Hematologic Malignancies Testing Market (by Diseases), $Million, 2022-2033
- Table 48: France Hematologic Malignancies Testing Market (by End User), $Million, 2022-2033
- Table 49: Denmark Hematologic Malignancies Testing Market, Test Volume (by Platform), Thousands, 2022-2033
- Table 50: Denmark Hematologic Malignancies Testing Market, Test Volume (by Diseases), Thousands, 2022-2033
- Table 51: Denmark Hematologic Malignancies Testing Market, Test Volume (by End User), Thousands, 2022-2033
- Table 52: Denmark Hematologic Malignancies Testing Market (by Product), $Million, 2022-2033
- Table 53: Denmark Hematologic Malignancies Testing Market (by Platform), $Million, 2022-2033
- Table 54: Denmark Hematologic Malignancies Testing Market (by Diseases), $Million, 2022-2033
- Table 55: Denmark Hematologic Malignancies Testing Market (by End User), $Million, 2022-2033
- Table 56: Rest-of-Europe Hematologic Malignancies Testing Market, $Million, 2022-2033
- Table 57: Rest-of-Europe Hematologic Malignancies Testing Market, Test Volume (by Platform), Thousands, 2022-2033
- Table 58: Rest-of-Europe Hematologic Malignancies Testing Market, Test Volume (by Diseases), Thousands, 2022-2033
- Table 59: Rest-of-Europe Hematologic Malignancies Testing Market, Test Volume (by End User), Thousands, 2022-2033
- Table 60: Rest-of-Europe Hematologic Malignancies Testing Market (by Product), $Million, 2022-2033
- Table 61: Rest-of-Europe Hematologic Malignancies Testing Market (by Platform), $Million, 2022-2033
- Table 62: Rest-of-Europe Hematologic Malignancies Testing Market (by Diseases), $Million, 2022-2033
- Table 63: Rest-of-Europe Hematologic Malignancies Testing Market (by End User), $Million, 2022-2033
- Table 64: Europe Hematologic Malignancies Testing Market, Key Development Analysis, January 2020-May 2024
